Veru (VERU) Share-based Compensation (2010 - 2026)
Veru (VERU) posted quarterly Share-based Compensation of $90860.0 for Q1 2026, down 95.91% year-over-year from $2.2 million in Q1 2025, and down 88.01% quarter-over-quarter from $757605.0 in Q4 2025.
Veru (VERU) Share-based Compensation (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Share-based Compensation for 17 consecutive years, with $90860.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 95.91% year-over-year to $90860.0; the TTM figure through Mar 2026 stood at $4.1 million (down 64.76% YoY), while the FY2025 annual figure was $8.1 million, down 40.62% from the prior year.
- Share-based Compensation retreated to $90860.0 in Q1 2026 per VERU's latest filing, from $757605.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.6 million in Q2 2023 and bottomed at -$12.8 million in Q3 2023.
- Historically, Share-based Compensation has averaged $1.0 million across 5 years, with a median of $2.1 million in 2022.
- Annual changes were most pronounced in 2023 — Share-based Compensation slumped 412.79% — and 2024, when it soared 4472.55%.
- Veru's Share-based Compensation stood at $257132.0 in 2022, then surged by 1224.98% to $3.4 million in 2023, then declined by 21.51% to $2.7 million in 2024, then sank by 71.67% to $757605.0 in 2025, then slumped by 88.01% to $90860.0 in 2026.
- Business Quant data shows VERU's Share-based Compensation at $90860.0 in Q1 2026, $757605.0 in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Veru | 59.70 Mn | 33.91 Mn | - | 577,969.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 577,969.00 |
| Jun 30, 2026 | 577,969.00 |
| Mar 31, 2026 | 90,860.00 |
| Mar 31, 2026 | 90,860.00 |
| Dec 31, 2025 | 757,605.00 |
| Dec 31, 2025 | 757,605.00 |
| Sep 30, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 2.67 Mn |
| Dec 31, 2024 | 2.67 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.63 Mn |